Pfizer and its partner Bristol Myers Squibb announced a new distribution partnership with Mark Cuban’s Cost Plus Drug Company to make the blood‑thinning medication Eliquis (apixaban) available through the online pharmacy, with the first shipments arriving on April 27, 2026.
Under the cost‑plus model, patients who obtain a prescription for Eliquis through Cost Plus Drugs will pay $345 for a 30‑day supply. The price reflects the manufacturer’s acquisition cost plus a 15% margin, a $5 dispensing fee, and a $5 shipping fee, providing a transparent and lower‑price alternative to the traditional pharmacy channel.
Eliquis has been a cornerstone of Pfizer’s and Bristol Myers Squibb’s portfolio, generating more than $14.4 billion in global sales in 2025 and $9.17 billion in 2024. The drug accounts for roughly 45 % of the anticoagulant market. With the foundational compound patent set to expire in September 2026 in the U.S. and generic competition expected thereafter, the partnership is a proactive move to preserve market share and revenue.
Pfizer’s 2025 financial results showed full‑year revenue of $62.6 billion, a 2 % operational decline from 2024, but a 6 % growth in non‑COVID products. The company guided for 2026 revenue of $59.5 to $62.5 billion, indicating confidence in maintaining profitability amid the approaching patent cliff.
“The BMS‑Pfizer Alliance is pleased to expand our direct‑to‑patient options for accessing Eliquis to the popular Cost Plus Drugs platform,” said Adam Lenkowsky, chief commercial officer at Bristol Myers Squibb. Mark Cuban added, “We’ve heard from a lot of people asking for Eliquis on Cost Plus Drugs, and this is about making sure they have a clearer, more direct way to access it.”
By offering Eliquis through a transparent, cost‑plus model, Pfizer and Bristol Myers Squibb aim to capture price‑sensitive patients, mitigate the impact of upcoming generic competition, and reinforce their direct‑to‑patient strategy, which also includes the 2025 Eliquis 360 Support program. The partnership positions the companies to sustain revenue from a key product while addressing the broader industry push for drug‑price transparency.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.